Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Your Article Summary
See Latest ArticlesThe impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis
International Journal of Cancer, 06/16/09
Zarogoulidis K et al. - In a study to examine the clinical impact of zoledronic acid (ZOL) with a focus on the survival, time to progression, and pain effect in lung cancer pts with bone metastases, it was concluded that the addition of ZOL increases overall survival in lung cancer pts with bone metastases. The longer the period of receiving ZOL, the better effect on survival and time to progression.
Methods- Lung cancer pts (n = 144, Stage IV) with evidence of metastasis bone scan were included.
- 87 of 144 experienced bone pain and received ZOL, 4 mg i.v. every 21 days (Group A), whereas the other 57 pts received no ZOL (Group B).
- All pts were treated with a combination chemotherapy that consisted of docetaxel 100 mg/m2 and carboplatin AUC = 6.
- Group A had a statistically significant longer survival when compared to Group B.
- A statistically significant positive correlation was found between number of cycles of therapy with ZOL and total patient survival and time to progression.
- Pain effect of ZOL had no significant difference between the 2 groups of pts.
- Urine N-telopeptide of type I collagen (NTx) levels decreased in pts with NTx ≤29 nM BCE/mM creatinine at baseline after treatment with ZOL.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI
The Journal of Nuclear Medicine, 08/19/09
Endoprosthetic proximal femur replacement: Metastatic versus primary tumors
Surgical Oncology, 11/05/09
Loss of p16INK4, alone and with overexpression of osteopontin, correlates with survival of patients with spinal metastasis from hepatocellular carcinoma
Medical Oncology, 10/19/09
Article Search
Sponsor